The Department of Veterans Affairs announced it will cover Leqembi, the Alzheimer’s drug manufactured by Eisai and Biogen, which received accelerated approval from the FDA in January, according to a March 13 company news release.
Read the full post on Becker's Hospital Review - Healthcare News
